FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034942408> ?p ?o ?g. }

• W2034942408 endingPage "25427" @default.
• W2034942408 startingPage "25414" @default.
• W2034942408 abstract "Abnormal proliferation and phenotypic modulation of pulmonary artery smooth muscle cells (PASMC) contributes to the pathogenesis of numerous cardiovascular disorders, including pulmonary arterial hypertension (PAH). The nuclear factor of activated T cells (NFAT) signaling pathway is linked to PASMC proliferation and PAH. MicroRNAs (miRNAs) are small non-coding RNAs that function in diverse biological processes. To systemically identify the specific miRNAs that regulate the NFAT pathway, a human primary miRNA library was applied for cell-based high throughput screening with the NFAT luciferase reporter system. Eight miRNAs were found to modulate NFAT activity efficiently. Of them, miR-124 robustly inhibited NFAT reporter activity and decreased both the dephosphorylation and the nuclear translocation of NFAT. miR-124 also inhibited NFAT-dependent transcription of IL-2 in Jurkat T cells. miR-124 exerted its effects by targeting multiple genes, including a known component of the NFAT pathway, NFATc1, and two new regulators of NFAT signaling, CAMTA1 (calmodulin-binding transcription activator 1) and PTBP1 (polypyrimidine tract-binding protein 1). Physiologically, miR-124 was down-regulated by hypoxia in human PASMC, consistent with the activation of NFAT during this process. Down-regulation of miR-124 was also observed in 3-week hypoxia-treated mouse lungs. Furthermore, the overexpression of miR-124 not only inhibited human PASMC proliferation but also maintained its differentiated phenotype by repressing the NFAT pathway. Taken together, our data provide the first evidence that miR-124 acts as an inhibitor of the NFAT pathway. Down-regulation of miR-124 in hypoxia-treated PASMC and its antiproliferative and prodifferentiation effects imply a potential value for miR-124 in the treatment of PAH.Background: The NFAT signaling pathway is linked to pulmonary arterial hypertension.Results: MicroRNA screening revealed that miR-124 robustly inhibits NFAT activity, dephosphorylation, and nuclear translocation of NFAT by targeting multiple genes, NFATc1, CAMTA1, and PTBP1.Conclusion: miR-124 is an effective and multipronged inhibitor of NFAT signaling.Significance: miR-124 might be a potential immunosuppressant that may have biological effects linked to pulmonary arterial hypertension. Abnormal proliferation and phenotypic modulation of pulmonary artery smooth muscle cells (PASMC) contributes to the pathogenesis of numerous cardiovascular disorders, including pulmonary arterial hypertension (PAH). The nuclear factor of activated T cells (NFAT) signaling pathway is linked to PASMC proliferation and PAH. MicroRNAs (miRNAs) are small non-coding RNAs that function in diverse biological processes. To systemically identify the specific miRNAs that regulate the NFAT pathway, a human primary miRNA library was applied for cell-based high throughput screening with the NFAT luciferase reporter system. Eight miRNAs were found to modulate NFAT activity efficiently. Of them, miR-124 robustly inhibited NFAT reporter activity and decreased both the dephosphorylation and the nuclear translocation of NFAT. miR-124 also inhibited NFAT-dependent transcription of IL-2 in Jurkat T cells. miR-124 exerted its effects by targeting multiple genes, including a known component of the NFAT pathway, NFATc1, and two new regulators of NFAT signaling, CAMTA1 (calmodulin-binding transcription activator 1) and PTBP1 (polypyrimidine tract-binding protein 1). Physiologically, miR-124 was down-regulated by hypoxia in human PASMC, consistent with the activation of NFAT during this process. Down-regulation of miR-124 was also observed in 3-week hypoxia-treated mouse lungs. Furthermore, the overexpression of miR-124 not only inhibited human PASMC proliferation but also maintained its differentiated phenotype by repressing the NFAT pathway. Taken together, our data provide the first evidence that miR-124 acts as an inhibitor of the NFAT pathway. Down-regulation of miR-124 in hypoxia-treated PASMC and its antiproliferative and prodifferentiation effects imply a potential value for miR-124 in the treatment of PAH. Background: The NFAT signaling pathway is linked to pulmonary arterial hypertension. Results: MicroRNA screening revealed that miR-124 robustly inhibits NFAT activity, dephosphorylation, and nuclear translocation of NFAT by targeting multiple genes, NFATc1, CAMTA1, and PTBP1. Conclusion: miR-124 is an effective and multipronged inhibitor of NFAT signaling. Significance: miR-124 might be a potential immunosuppressant that may have biological effects linked to pulmonary arterial hypertension." @default.
• W2034942408 created "2016-06-24" @default.
• W2034942408 creator A5004092071 @default.
• W2034942408 creator A5006650935 @default.
• W2034942408 creator A5007017045 @default.
• W2034942408 creator A5023177869 @default.
• W2034942408 creator A5028880587 @default.
• W2034942408 creator A5029524587 @default.
• W2034942408 creator A5036726416 @default.
• W2034942408 creator A5040647242 @default.
• W2034942408 creator A5072994758 @default.
• W2034942408 creator A5077936202 @default.
• W2034942408 creator A5082213642 @default.
• W2034942408 creator A5082653594 @default.
• W2034942408 date "2013-08-01" @default.
• W2034942408 modified "2023-10-11" @default.
• W2034942408 title "MicroRNA-124 Suppresses the Transactivation of Nuclear Factor of Activated T Cells by Targeting Multiple Genes and Inhibits the Proliferation of Pulmonary Artery Smooth Muscle Cells" @default.
• W2034942408 cites W1541012296 @default.
• W2034942408 cites W1597198747 @default.
• W2034942408 cites W1971416757 @default.
• W2034942408 cites W1974512564 @default.
• W2034942408 cites W1978337436 @default.
• W2034942408 cites W1981956565 @default.
• W2034942408 cites W1986643307 @default.
• W2034942408 cites W1996630410 @default.
• W2034942408 cites W2001993336 @default.
• W2034942408 cites W2010461414 @default.
• W2034942408 cites W2013752448 @default.
• W2034942408 cites W2017426710 @default.
• W2034942408 cites W2025593289 @default.
• W2034942408 cites W2026686516 @default.
• W2034942408 cites W2026939372 @default.
• W2034942408 cites W2038874091 @default.
• W2034942408 cites W2042916026 @default.
• W2034942408 cites W2043251840 @default.
• W2034942408 cites W2048085771 @default.
• W2034942408 cites W2051206320 @default.
• W2034942408 cites W2056147363 @default.
• W2034942408 cites W2061725286 @default.
• W2034942408 cites W2062002285 @default.
• W2034942408 cites W2065501812 @default.
• W2034942408 cites W2069337669 @default.
• W2034942408 cites W2070002665 @default.
• W2034942408 cites W2073580835 @default.
• W2034942408 cites W2077259663 @default.
• W2034942408 cites W2079278462 @default.
• W2034942408 cites W2083381199 @default.
• W2034942408 cites W2087056964 @default.
• W2034942408 cites W2093714359 @default.
• W2034942408 cites W2096887117 @default.
• W2034942408 cites W2100358595 @default.
• W2034942408 cites W2104577103 @default.
• W2034942408 cites W2107435629 @default.
• W2034942408 cites W2111969156 @default.
• W2034942408 cites W2112818390 @default.
• W2034942408 cites W2113103309 @default.
• W2034942408 cites W2117802141 @default.
• W2034942408 cites W2119200777 @default.
• W2034942408 cites W2121747833 @default.
• W2034942408 cites W2121822802 @default.
• W2034942408 cites W2128940917 @default.
• W2034942408 cites W2134183254 @default.
• W2034942408 cites W2135412450 @default.
• W2034942408 cites W2135783216 @default.
• W2034942408 cites W2137354848 @default.
• W2034942408 cites W2145021085 @default.
• W2034942408 cites W2147550605 @default.
• W2034942408 cites W2152673117 @default.
• W2034942408 cites W2152702315 @default.
• W2034942408 cites W2157973267 @default.
• W2034942408 cites W2160284187 @default.
• W2034942408 cites W2162674813 @default.
• W2034942408 cites W2166098285 @default.
• W2034942408 cites W2166502047 @default.
• W2034942408 cites W2166967514 @default.
• W2034942408 cites W2171559697 @default.
• W2034942408 cites W2548599454 @default.
• W2034942408 doi "https://doi.org/10.1074/jbc.m113.460287" @default.
• W2034942408 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3757204" @default.
• W2034942408 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23853098" @default.
• W2034942408 hasPublicationYear "2013" @default.
• W2034942408 type Work @default.
• W2034942408 sameAs 2034942408 @default.
• W2034942408 citedByCount "110" @default.
• W2034942408 countsByYear W20349424082014 @default.
• W2034942408 countsByYear W20349424082015 @default.
• W2034942408 countsByYear W20349424082016 @default.
• W2034942408 countsByYear W20349424082017 @default.
• W2034942408 countsByYear W20349424082018 @default.
• W2034942408 countsByYear W20349424082019 @default.
• W2034942408 countsByYear W20349424082020 @default.
• W2034942408 countsByYear W20349424082021 @default.
• W2034942408 countsByYear W20349424082022 @default.
• W2034942408 countsByYear W20349424082023 @default.
• W2034942408 crossrefType "journal-article" @default.
• W2034942408 hasAuthorship W2034942408A5004092071 @default.
• W2034942408 hasAuthorship W2034942408A5006650935 @default.
• W2034942408 hasAuthorship W2034942408A5007017045 @default.

• next